Cannabinoid signaling and liver therapeutics

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Volume 63, Issue 1, Pages (July 2015)
Inflammasomes in liver diseases
Oxidants and antioxidants in alcohol-induced liver disease
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review  Christian Thoma, Christopher P. Day, Michael.
Tiny RNA with great effects: miR-155 in alcoholic liver disease
Hepatic CD141+IFNλ+ DC subset: One against all?
Pathological roles of purinergic signaling in the liver
The yin and yang of evasion and immune activation in HCC
Pathways of liver injury in alcoholic liver disease
The inflammasome in liver disease
Reactive oxygen species in the normal and acutely injured liver
Obesity, inflammation, and liver cancer
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
Oxidants and antioxidants in alcohol-induced liver disease
Volume 47, Issue 1, Pages (July 2007)
Thoetchai (Bee) Peeraphatdit, Douglas A. Simonetto, Vijay H. Shah 
Agustín Albillos, Margaret Lario, Melchor Álvarez-Mon 
Hepatitis C-associated B-cell non-Hodgkin lymphomas
Volume 41, Issue 3, Pages (September 2004)
Roles for Chemokines in Liver Disease
Nicolas Moniaux, Jamila Faivre  Journal of Hepatology 
Volume 64, Issue 1, Pages (January 2016)
Volume 55, Issue 4, Pages (October 2011)
Volume 134, Issue 2, Pages (February 2008)
Biology of the immunomodulatory molecule HLA-G in human liver diseases
ChREBP in NASH – A liver transcription factor comes in from the cold
Ludger Scheja, Joerg Heeren  Journal of Hepatology 
Marina Berenguer, Detlef Schuppan  Journal of Hepatology 
Targeting the gut-liver axis in liver disease
Inflammation and portal hypertension – The undiscovered country
From immunosuppression to tolerance
Hepatitis C core protein – The “core” of immune deception?
Signalling pathways in alcohol-induced liver inflammation
Sugar, Sugar Not So Sweet for the Liver
I. Carmona, P. Cordero, J. Ampuero, A. Rojas, M. Romero-Gómez 
Targeting gut flora to prevent progression of hepatocellular carcinoma
Amalia Gastaldelli, Giulio Marchesini  Journal of Hepatology 
Mechanisms of iron hepatotoxicity
Ariane Mallat, Sophie Lotersztajn  Journal of Hepatology 
The yin and yang of evasion and immune activation in HCC
Volume 61, Issue 1, Pages S69-S78 (November 2014)
Volume 45, Issue 4, Pages (October 2006)
Volume 59, Issue 3, Pages (September 2013)
Pathways of liver injury in alcoholic liver disease
Bin Gao, Hua Wang, Fouad Lafdil, Dechun Feng  Journal of Hepatology 
The genetics of alcohol dependence and alcohol-related liver disease
Volume 63, Issue 2, Pages (August 2015)
Senescence in chronic liver disease: Is the future in aging?
Claire Z. Larter, Geoffrey C. Farrell  Journal of Hepatology 
Volume 59, Issue 2, Pages (August 2013)
Arjan Boltjes, Dowty Movita, André Boonstra, Andrea M. Woltman 
NASH animal models: Are we there yet?
Volume 61, Issue 1, Pages S79-S90 (November 2014)
Salvatore Papa, Concetta Bubici  Journal of Hepatology 
Role of desmoplasia in cholangiocarcinoma and hepatocellular carcinoma
Volume 63, Issue 1, Pages (July 2015)
Macrophage heterogeneity in liver injury and fibrosis
The dynamic biliary epithelia: Molecules, pathways, and disease
Autophagy in liver diseases: Time for translation?
Silvia Affò, Ramón Bataller  Journal of Hepatology 
Statins: Old drugs as new therapy for liver diseases?
Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease  Michal Pawlak,
Pathogenesis of cholestatic hepatitis C
Inflammatory pathways in alcoholic steatohepatitis
Foxa1 and Foxa2 regulate bile duct development in mice
Volume 61, Issue 2, Pages (August 2014)
Shih-Yen Weng, Detlef Schuppan  Journal of Hepatology 
Sander Lefere, Frank Tacke  JHEP Reports 
Platelets arrive at the scene of fibrosis……studies
Presentation transcript:

Cannabinoid signaling and liver therapeutics Ariane Mallat, Fatima Teixeira-Clerc, Sophie Lotersztajn  Journal of Hepatology  Volume 59, Issue 4, Pages 891-896 (October 2013) DOI: 10.1016/j.jhep.2013.03.032 Copyright © 2013 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Cellular targets of CB1-mediated effects during liver injury. CB1 receptors expressed in hepatocytes and hepatic myofibroblasts contribute to high fat diet and alcohol-induced steatosis, liver regeneration, and fibrogenesis. Steatogenic properties of CB1 result from hepatocyte activation of lipogenesis, reduction of fatty acid oxidation, and decreased release of TG-rich VLDL, combined to CB1-dependent release of free fatty acids from the adipose tissue. While anandamide binding to CB1 receptors drives metabolic steatois, 2-AG is the endogenous ligand promoting alcoholic steatosis. CB1 also activates hepatocyte proliferation and promotes fibrogenesis by enhancing hepatic myofibroblast survival. Journal of Hepatology 2013 59, 891-896DOI: (10.1016/j.jhep.2013.03.032) Copyright © 2013 European Association for the Study of the Liver Terms and Conditions

Fig. 2 Hepatic cellular targets of CB2-mediated protective effects. CB2 receptors expressed in immune cells (Kupffer cells, Th17 lymphocytes) and hepatic myofibroblasts display anti-inflammatory properties and protect against alcohol-induced steatosis, hepatocyte apoptosis, and fibrogenesis. Antifibrogenic properties result from (i) direct CB2-mediated effects on hepatic myofibroblasts and (ii) indirect hepatoprotective effects on hepatocytes, anti-inflammatory properties on Kupffer cell and downregulation of the production of the profibrogenic cytokine IL17 by Th17 lymphocytes. Journal of Hepatology 2013 59, 891-896DOI: (10.1016/j.jhep.2013.03.032) Copyright © 2013 European Association for the Study of the Liver Terms and Conditions

Journal of Hepatology 2013 59, 891-896DOI: (10. 1016/j. jhep. 2013. 03 Copyright © 2013 European Association for the Study of the Liver Terms and Conditions